According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is $0.82 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2023-12-31 | $0.82 B | 11.29% |
2022-12-31 | $0.74 B | 24.98% |
2021-12-31 | $0.59 B | 112.25% |
2020-12-31 | $0.27 B | 230.17% |
2019-12-31 | $84.65 M | 36.93% |
2018-12-31 | $61.82 M | 12.98% |
2017-12-31 | $54.72 M | 1.86% |
2016-12-31 | $53.72 M | 78.02% |
2015-12-31 | $30.17 M | 0.6% |
2014-12-31 | $30 M | 0% |
2013-12-31 | $30 M | 0% |
2012-12-31 | $30 M | 0% |
2011-12-31 | $30 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $24.98 B | 2,928.18% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $22.93 B | 2,679.73% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | $1.39 B | 69.28% | ๐บ๐ธ USA |
Repligen
RGEN | $0.71 B | -13.74% | ๐บ๐ธ USA |
Novavax NVAX | $0.22 B | -72.24% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $2.54 M | -99.69% | ๐บ๐ธ USA |
NanoViricides NNVC | $1.5 M | -99.82% | ๐บ๐ธ USA |
Cel-Sci
CVM | $13.09 M | -98.41% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $0.86 B | 4.25% | ๐บ๐ธ USA |